NFKB1 and Crohn disease: Our results provide new treatment targets, for example, the MAPK pathway in all types of IBD, in ileal Crohn’s disease the JAK-STAT1/2 pathway, and in patients refractory to anti-TNFα treatment the NFκB, TGFβ, and JAK-STAT3 pathways.